ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumou
Circadian Technologies announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.